NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 69 filers reported holding NURIX THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,857,314 | -11.4% | 363,526 | +12.7% | 0.00% | 0.0% |
| Q2 2023 | $3,223,253 | -32.9% | 322,648 | -40.3% | 0.00% | 0.0% |
| Q1 2023 | $4,801,504 | -29.7% | 540,710 | -13.0% | 0.00% | -50.0% |
| Q4 2022 | $6,825,695 | -36.5% | 621,648 | -24.7% | 0.00% | 0.0% |
| Q3 2022 | $10,751,000 | +155.7% | 825,079 | +148.6% | 0.00% | +100.0% |
| Q2 2022 | $4,204,000 | -5.0% | 331,843 | +5.1% | 0.00% | 0.0% |
| Q1 2022 | $4,423,000 | -50.5% | 315,666 | +2.3% | 0.00% | -50.0% |
| Q4 2021 | $8,931,000 | +139.0% | 308,487 | +147.4% | 0.00% | +100.0% |
| Q3 2021 | $3,737,000 | -49.8% | 124,715 | -55.6% | 0.00% | -50.0% |
| Q2 2021 | $7,451,000 | -31.0% | 280,852 | -19.1% | 0.00% | -33.3% |
| Q1 2021 | $10,791,000 | +105.7% | 347,093 | +117.5% | 0.00% | +200.0% |
| Q4 2020 | $5,246,000 | – | 159,549 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |